Treatment of ADHD: Guanfacine Extended Release in ADHD
Investigators at Massachusetts General Hospital, Boston, MA, performed a multicenter, 9-week, double-blind, placebo-controlled, dose-optimization study of guanfacine extended release (GXR, <4 mg/d) adjunctive to a long-acting psychostimulant for ADHD continued in 461 subjects.
| Published in: | Pediatric Neurology Briefs |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
Pediatric Neurology Briefs Publishers
2014-08-01
|
| Subjects: | |
| Online Access: | https://www.pediatricneurologybriefs.com/articles/129 |